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Abstract
Background: The main aim of this study was to determine the prevalence of US-detectable forefoot bursae,
metatarsophalangeal (MTP) joint and metacarpophalangeal (MCP) joint synovial hypertrophy (SH), Power Doppler
(PD) signal or erosion in participants with systemic lupus erythematosus (SLE). A secondary aim was to determine
the strength of potential association between patient reported foot-related disability and US-detected forefoot
bursae, MTP joint SH, PD signal or erosion in participants with SLE.
Method: A cross-sectional observational study of 20 participants with SLE was completed to determine the prevalence
of US-detected forefoot bursal, MTP and MCP joint pathology. Patient-reported foot-related impairment and activity
limitation (accumulatively referred to as disability) were also recorded. Spearmans’ Rank Correlation analyses were
completed to determine the potential strength of association between US-detected pathology and patient
report disability.
Results: The prevalence of MTP joint SH and PD was 80 % (16/20) and 10 % (2/20), respectively. The prevalence of MCP
joint SH and PD was 60 % (12/20) and 30 % (6/20) respectively. A significant association was noted between PD scores
for the MTP joints and MCP joints (r = 0.556; p = 0.011) although this was not demonstrated for SH scores (r = 0.
176; p = 0.459). Significant associations between forefoot bursal prevalence and MTP joint PD were noted (r = 0.
467; p = 0.038). The prevalence of bursae and bursal PD (grade 2 or above) was 100 % (20/20) and 10 % (2/20),
respectively. Moderate foot-related impairment and activity limitation was reported by 95 and 85 % of participants
respectively.
Conclusion: This pilot study suggests that US-detected MTP, MCP joint and forefoot bursal abnormalities may be
prevalent in participants with SLE and they may experience a moderate level of foot-related disability. Further
research is required to substantiate these preliminary findings.
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Background
Systemic lupus erythematosus (SLE) is a chronic, auto-
immune, inflammatory disorder of unknown aetiology that
affects multiple organs including skin, soft tissues and joints
[1]. In other similar inflammatory diseases like rheumatoid
arthritis (RA), modern imaging techniques have demon-
strated a high prevalence of foot problems that significantly
reduce mobility and health-related quality of life [2]. How-
ever, the prevalence and impact of such problems in partici-
pants with SLE have not been well established to date and
consequently there may be an unmet burden of poor foot
health in this patient group despite previous evidence of
metatarsophalangeal joint involvement [3].
Joint involvement in patients with SLE is common and
it can have a significant impact upon the patients’ health-
related quality of life [1]. This can reportedly vary from
transient migratory arthralgia without objective evidence
of synovitis to an erosive arthritis similar to RA [4]. There
has been ongoing debate about whether this latter group
represents an overlap of RA and SLE (rhupus) or a distinct
subset of SLE [4, 5]. However, compared to other inflam-
matory arthropathies, joint disease in SLE has not been
studied in much detail and the affectation of the metacar-
pophalangeal (MCP) joints or metatarsophalangeal (MTP)
joints comparatively less well reported, particularly using
US examination [4, 5].
The foot is a complex structure with numerous small
anatomical details and differentiating between symptoms
resulting from synovial hypertrophy, joint synovitis, teno-
synovitis or bursitis can be problematic [2]. Clinical exam-
ination alone has been shown to be relatively insensitive to
these features [6] and this is particularly relevant when the
aim is to establish more targeted therapeutic approaches
for patients with rheumatic conditions. Typically, MTP
joint synovitis is associated with forefoot metatarsalgia
and is thought to be due to the synovial lining becoming
enlarged and inflamed as part of inflammatory disease
[1, 2, 6]. Additionally, numerous small, synovially-lined
bursae also exist throughout the forefoot and it is hypothe-
sised that these may also become symptomatic as a conse-
quence of poorly regulated inflammatory processes [2, 7].
However, it is unclear to date, to what extent patients with
connective tissue disease, such as SLE, may also experience
these pathological joint and tissue features.
Data from the FeeTURA programme of research sug-
gests that US can readily differentiate between MTP joint
hypertrophy, synovitis, bursal hypertrophy and bursitis as
well as identify soft tissue pathology within the feet, which
are not clinically apparent in patients with RA [2, 7, 8]. It
is proposed that this technique may also be feasibly con-
ducted in participants with SLE, although to our know-
ledge, this has not been trialed or reported to date. US has
been widely used in RA to identify the extent of joint in-
volvement as well as inform treatment decisions [9–11].
However, very few studies have used such assessments in
participants with SLE to date [3]. Moreover, these studies
have had relatively small numbers of participants and,
apart from a recent study which also looked at abnormal-
ities of MTP joints [3], they have mainly focussed upon
wrist, hand or knee involvement [5, 12]. To our know-
ledge, this is therefore, the first study to explore the use of
US for the investigation of MTP joint, MCP joint and
forefoot bursal abnormalities in participants with SLE.
The main aim of this study was to determine the preva-
lence of US-detectable forefoot bursae, MTP joint and
MCP joint hypertrophy, Doppler signal or erosion in par-
ticipants with SLE. A secondary aim was to determine the
strength of potential association between patient reported
foot-related disability and US-detected forefoot bursae,
MTP joint hypertrophy, Doppler signal or erosion.
Methods
Study design
A cross-sectional, observational, study design was used
for this project. The related study null hypotheses were
defined as follows: (i) participants with SLE demonstrate
no US-detectable pathology of the MTP joints or MCP
joints and no reported foot-related disability, and (ii)
there is no significant association between US-detectable
forefoot pathology and reported disability in participants
with SLE.
Ethics, consent and permissions
Ethical approval for the study was obtained from the
United Kingdom (UK) National Research Ethics Service
(NRES) Committee North East Sunderland (13/NE/0161)
and the study conducted in accordance with the Dec-
laration of Helsinki guidelines for research (1975). All
participants gave written informed consent and data
was collected at the time of each participant’s scheduled
rheumatology outpatient appointment.
Participants
Individuals with a diagnosis of SLE confirmed by a con-
sultant rheumatologist and fulfilling American College
of Rheumatology (ACR) criteria [13] were consecutively
and prospectively recruited from adult patients attending
a UK rheumatology outpatient clinic. The 1997 criteria
were pragmatically selected as these are used within the
clinical environment in which the study was conducted
[4]. As a novel pilot study, a sample size of 20 partici-
pants was pragmatically selected. Patients who had cor-
ticosteroid injection intramuscularly or to the forefoot
or hand within the previous 3 months prior to study start,
those with a diagnosis of concomitant musculoskeletal
disease (e.g. primary osteoarthritis or gout), and those un-
able or unwilling to give consent were excluded from the
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study. All participants within this study had not received
previous podiatry treatment or orthotic intervention.
Assessment of disease activity
The Safety of Estrogens in Lupus Erythematosus National
Assessment – Systemic Lupus Erythematosus Disease
Activity Index (SELENA-SLEDAI) score was used to deter-
mine disease activity in participants with SLE [14]. This is a
composite measure of organ and body system affectation as
a consequence of SLE disease activity. An accumulative
score is calculated following physician completion. The
score range is from 0 to 105; where 0 indicates low disease
activity and 105 indicates high disease activity. The
presence of Rheumatoid factor, a blood borne immune
marker, was also determined. The presence of this
marker may indicate that a person could potentially
have an overlap of disease between SLE and rheuma-
toid arthritis, which may lead to confounding when
interpreting the findings of this study.
US scan protocol
Grey scale (GS) and Power Doppler (PD) images were ob-
tained using a diagnostic US scanner [Esaote MyLab70®].
All MTP joints and intermetatarsal spaces were imaged
from dorsal and plantar approaches and in longitudinal
and transverse planes using an 8-16 MHz linear array
transducer. Simultaneous US assessment of MCP joints
was conducted to compare disease activity in these joints
with those of the MTP joints. All US scanning was per-
formed in accordance with British Medical Ultrasound
Society guidelines for safe use [15] and completed by an
in-house trained researcher (SM). The reliability of this
US protocol has been previously reported as moderate to
substantial [8].
Joint synovial hypertrophy (SH) was identified as
non-compressible hypoechoic intra-articular tissue on
GS and graded between 0 and 3 (grade 0 = none; grade
1 = hypoechoic/anechoic line beneath joint capsule;
grade 2 = elevation of joint capsule parallel to joint area,
and grade 3 = bulge extending to at least one bone
diaphysis either proximally or distally) [9–11]. The SH
grades (0–3) for the 10 MCPJs or 10 MTPJs for each
participants were combined to give an overall possible
score range of 0–30 for the hands and feet respectively.
PD activity was also graded semi-quantitatively as 0–3
(grade 0 = no flow; grade 1 = single-vessel signals; grade
2 = less than 50 % area of synovium filled with vessels
and grade 3 = more than 50 % area of synovium filled
with vessels) [10]. PD scores were combined as per SH
scores for each participant to give an overall MCP joint
or MTP joint score range of 0–30.
Intermetatarsal lesions were classified as hypertrophied
bursae if a defined region of hypoechogenicity within inter-
metatarsal spaces, either inferior or superior to the deep
transverse intermetatarsal ligament, was observed in trans-
verse and longitudinal scanning planes, in a classification
system consistent to that previously reported [2, 7, 8, 16].
Submetatarsal lesions were classified as hypertrophied bur-
sae if a defined region of hypoechogenicity inferior to the
base of metatarsal heads was observed similarly. For every
participant, the presence or absence of bursa at each site
was recorded giving a possible total score of 0–18 (5 sub-
metatarsal and 4 intermetatarsal bursa in each foot) [8, 16].
Subsequently, the US grading (0–3) for PD signal obtained
from each of the 18 bursal regions were combined to give
a possible score range of 0–54.
Erosion was noted as present if a distinct loss in cortical
bone was observed in two perpendicular scanning planes
[10]. The total number of erosions identified for each
participant was combined to give an overall MCP joint or
MTP joint score range of 0–10.
Assessment of patient-reported disability
Patient-reported foot-related impairment and activity limi-
tation was assessed using the ‘Foot Impact Scale’ (FIS)
questionnaire [17]. This questionnaire has two subscales:
‘foot impairment and footwear restriction’ (FISIF, score
range 0–21) and ‘activity limitation and participation re-
striction’ (FISAP, score range 0–29), and it has previously
been validated for use in patients with rheumatoid arthritis
[17]. An elevated FISIF or FISAP score indicates greater foot
impairment or activity limitation, respectively. Henceforth,
the FISIF subscale will be referred to as ‘foot impairment’
and the FISAP subscale as ‘activity limitation’. The FIS
questionnaire was selected because, to our knowledge, this
is the only tool with foot related subscales that differentiate
disability from pain. We are not aware of any currently
validated tools for the evaluation of patient-reported foot-
related disability in participants with SLE.
Analysis
All analysis was completed using Stata version 11.0 (Stata
Corp, USA), or SPSS version 18.0 (Chicago, USA). Prior to
analysis, data was checked for inconsistencies, outliers,
missing information and distribution. Participant char-
acteristic data measured using a continuous scale are
presented as means and standard deviations (SDs) if ap-
proximately normally distributed, and as medians and
inter-quartile ranges (IQRs) if skewed. Statistical signifi-
cance was reported at 5 % (i.e. p < 0.05) confidence
level, based upon two-tailed analysis.
All variables undergoing correlation analysis were identi-
fied as negatively skewed, and as such, a non-parametric
test of association (Spearman’s Rank Correlation Coef-
ficient) was used. Tests of association were explored
between hand and foot data, and US variables and patient-
reported foot impairment or activity limitation.
Mukherjee et al. Journal of Foot and Ankle Research  (2016) 9:27 Page 3 of 6
Results
The mean (SD) age of participants was 53.6 (12.8) years.
There were 18 females and 2 males. Mean (SD) disease
duration was 12.1 (7.6) years and overall disease activity
was low with the median SELENA-SLEDAI score for the
cohort being 0 (IQR: 0 to 1). All participants were in
receipt of disease modifying agents and 55 % (11) were
receiving oral steroids with median daily Prednisolone
dose of 10 mg (IQR: 5 to 15 mg). Rheumatoid factor
(RF) was negative in eleven (55 %) and positive in five
(25 %) of the participants. RF status was not known for
the remaining four participants.
The US findings have been summarised in Table 1. The
prevalence of MTP joint SH and PD was 80 % (16/20) and
10 % (2/20), respectively. The prevalence of MCP joint SH
and PD was 60 % (12/20) and 30 % (6/20), respectively.
Overall, a number of participants demonstrated SH in
at least one MTP or MCP joint. PD grade 1 or above in
at least one MTP or MCP joint was seen in two and six
participants, respectively. One participant had PD grade
2 observed in an MCP joint. All participants demonstrated
at least one hypertrophied bursa with PD grade 1 signal.
Two participants had a single bursa with PD grade 2 or
above. Thus, the first null hypothesis can be rejected.
Correlation analysis determined that those participants
with SH in their MTP joints did not necessarily also have
it in their MCP joints (r = 0.176; p = 0.459). However, a
significant association was noted between PD scores for
the MTP joints and MCP joints (r = 0.556; p = 0.011).
A significant associations between forefoot bursal preva-
lence and MTP joint PD was noted (r = 0.467; p = 0.038),
but this was not observed between bursal prevalence and
MCP joint PD (r = 0.577; p = 0.133). Additionally, a signifi-
cant association between bursal PD and MTP joint PD
was noted (r = 0.460; p = 0.041).
Characteristics of participants and their respective foot
impairment and activity limitation scores have been sum-
marised in Table 2. Foot-related impairment or activity
limitation was reported by 95 and 85 % of participants,
respectively. The median score for foot impairment was
11 (IQR: 4.8 to 14.0) and activity limitation was 11.5 (IQR:
1.0 to 20.5).
Patient-reported foot impairment and activity limita-
tion were not significantly associated with MTP joint
SH (r = −0.044; p = 0.852 and r = −0.170; p = 0.474, respect-
ively), MTP joint PD (r = 0.333; p = 0.151 and r = 0.421; p =
0.065, respectively), prevalence of bursa (r = 0.237; p = 0.314
and r = 0.186; p = 0.433, respectively), or bursal PD (r=
0.274; p = 0.243 and r = 0.379; p = 0.099, respectively). Thus,
the second null hypothesis can be accepted.
Discussion
This pilot study suggests that US detected synovial and
bursal abnormalities within the MTP and MCP joints of
participants with SLE are prevalent and hence, could be
potentially under-recognised clinically. A significant
association between US-detectable MTP joint Doppler
activity and bursa was noted. Additionally, participants
reported moderate levels of foot-related impairment and
activity limitation, respectively, which could be considered
comparable to that reported by patients with RA [7].
However, unlike previous work in participants with RA,
no association between US-detected joint pathology and
patient reported disability was observed in this study [7].
It is currently not possible to comparatively evaluate the
prevalence of US-detected pathology found in this study
as to our knowledge, this is the first pilot study to do so.
The prevalence of US detected MTP and MCP joint
and forefoot bursal abnormalities in a cohort of partici-
pants with relatively low systemic markers of SLE activity
shown in this study suggests that there may be a persistent
level of disease activity that is clinically under-recognised.
Conversely, the presence of joint hypertrophy or bursal
lesions may be related not to inflammatory disease but
mechanical tissue irritation. Further work is required to
fully appreciate the clinical interpretation of increased
forefoot bursae in this participant group. Similarly, the
moderate levels of patient reported foot-related impairment
and activity limitation may represent a further independent
or related unmet foot health burden. Nonetheless, this pilot
data suggests that there may be a need for further US
examination to fully appreciate disease activity and preva-
lence in this patient group. However, the aetiology and/or
risk factors leading to these findings remain unclear.
Although joint and bursal abnormalities within the fore-
feet were apparent in this pilot study, they do not appear
to be significantly associated with reported foot-related
impairment or activity limitation. However, the sample
size for this study is small and as such association analyses
of this kind are potentially subject to related bias and
error. Nonetheless, the findings suggest the need for fur-
ther research to fully appreciate the potential burden of
Table 1 Summary findings of musculoskeletal US scanning of
the forefeet and hands
Prevalence % (n) Median Score Interquartile range
MCP Joint SH 60 (12) 1.5 0–3.75b
MCP Joint PD 30 (6) 0.0 0–1b
MTP Joint SH 80 (16) 2.0 1–2b
MTP Joint PD 10 (2) 0.0 0–0b
Bursaa present 100 (20) 9.5 8–11.75c
Bursaa PD 100 (20) 3.0 2–3.75d
aSubmetatarsal and intermetatarsal bursa
bOut of a possible combined score range of 0–30(using US grading of 0 to 3
for both SH and PD for each of the 10 MCP and10 MTP joints)
cOut of a possible score range of 0–18 (5 submetatarsal and 4 intermetatarsal
bursa on each foot)
dOut of a possible combined score range of 0–54 (using US grading of 0 to 3
for each of the 18 bursal spaces imaged per patient)
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poor foot health in patients with SLE, the associated risk
factors and thus potential therapeutic targets.
This study has several potential limitations. Firstly, as
a pilot study, a small number of participants were included.
Further studies with larger numbers of participants are
needed to substantiate any trends shown here. Secondly,
the cohort of participants with SLE studied generally had
mild disease and fuller data regarding disease status or eth-
nicity is required. Future studies could investigate partici-
pants across the spectrum of disease severity, including
those at the severe end. Moreover, anti-CCP (anti-cyclic
citrullinated peptide) antibody status for all participants
could be determined and those testing positive excluded
from the study to rule out possibility of any overlap with
RA [1, 4, 13]. In addition, evaluation of potential confound-
ing factors (e.g. presence of concomitant disease) would be
feasible with replication of this protocol in a larger cohort,
and the data presented here may be used to inform such
sample size calculations. Thirdly, the 2012 ACR classifica-
tion criteria were not used and the 1997 criteria were prag-
matically selected as these are used within the clinical
environment in which the study was conducted [4]. Finally,
there are no current guidelines as to the minimum
standards of sonography training in order to undertake
and use US within clinical or research practice, especially
with regards to standardised approaches in participants
with SLE [9, 15, 18]. The physician undertaking the US
examination as part of this study (SM) has received
substantial ‘in-house’ training, which has previously been
shown to have good intra-rater agreement, however it
should be acknowledged that he is not a full-time
Sonographer [8]. There is a need for standardisation of
US protocols of the foot and ankle (including probe selection
and machine settings) and training requirements to help en-
sure consistency and accuracy in approach. For example,
arguably, a higher frequency probe may allow improved visu-
alisation of superficial structures, whilst a lower frequency
probe would do the converse; thus appropriate probe selec-
tion and availability may influence image acquisition and
interpretation accuracy [3, 9]. Standardisation of such proto-
col elements will further assure clinicians as to the accuracy
of research that is conducted using this technique.
Conclusion
In this novel work, participants with SLE were shown to
have a high prevalence of US-detectable MTP and MCP
joint SH, PD and bursal abnormalities. Additionally, this
patient group reported moderate levels of foot-related
impairment and activity limitation. The data presented
can be used to inform the basis for future larger cohort
investigations with potentially high clinical relevance to
the ongoing foot health of patients with SLE.
Table 2 Demographic characteristics of 20 SLE participants and their self-reported foot impairment and activity limitation
Participants Age (years) Sex Duration of SLE (years) RF positivity FISIF FISAP
1 46 Female 9 Negative 12 1
2 51 Female 5 Positive 8 10
3 66 Female 36 Negative 13 1
4 56 Female 18 Negative 10 19
5 40 Female 14 - 1 0
6 55 Female 19 Positive 9 2
7 62 Female 11 Negative 15 21
8 41 Female 2 - 4 0
9 60 Female 13 Positive 18 17
10 63 Female 15 Positive 0 0
11 57 Female 9 Negative 16 29
12 45 Female 12 - 9 11
13 60 Male 8 Negative 7 7
14 63 Male 7 Positive 13 16
15 38 Female 14 Negative 14 21
16 73 Female 7 - 14 27
17 64 Female 5 Negative 13 11
18 67 Female 22 Negative 4 8
19 44 Female 8 Negative 3 1
20 20 Female 7 Negative 16 22
FISIF foot impairment and footwear restriction
FISAP activity limitation and participation restriction
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